The study will be conducted to investigate the pharmacokinetics of ceftaroline during continuous and intermittent renal replacement therapy.

Inclusion Criteria:

• Age >18 years, able to give written informed consent
• Suspected or proven bacterial infection requiring parenteral antibiotic therapy.
• Renal replacement therapy (continuous or intermittent)

Exclusion Criteria:

• Known hypersensitivity to ceftaroline or other cephalosporins, or severe hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents.
• An expected survival of less than two days.
• Known pregnancy
• Coadministration of valproic acid or probenecid, which cannot be discontinued for the duration of the study
• Ceftaroline as monotherapy for resistent species or fungal infections.
• Other reasons oposing the study participation on the discretion of the investigators